Phosphorylation of p21 in G₂/M Promotes Cyclin B-Cdc2 Kinase Activity

REFERENCES

• Adams, P. D., W. R. Sellers, S. K. Sharma, A. D. Wu, C. M. Nalin, and W. G. Kaelin, Jr. 1996. Identification of a cyclin-Cdk2 recognition motif present in substrates and p21-like cyclin-dependent kinase inhibitors. Mol. Cell. Biol. 16:6623–6633.
   PubMed Web of Science ®Google Scholar
• Agami, R., and R. Bernards. 2000. Distinct initiation and maintenance mechanisms cooperate to induce G1 cell cycle arrest in response to DNA damage. Cell 102:55–66.
   PubMed Web of Science ®Google Scholar
• Akiyama, T., T. Yoshida, T. Tsujita, M. Shimizu, T. Mizukami, M. Okabe, and S. Akinaga. 1997. G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/Waf1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells. Cancer Res. 57:1495–1501.
   PubMed Web of Science ®Google Scholar
• Asada, M., T. Yamada, H. Ichijo, D. Delia, K. Miyazono, and K. Fukumuro. 1999. Apoptosis inhibitory activity of cytoplasmic p21 Cip1/Waf1 in monocytic differentiation. EMBO J. 18:1223–1234.
   PubMed Web of Science ®Google Scholar
• Brugarolas, J., C. Chandrasekaran, J. I. Gordon, D. Beach, T. Jacks, and G. J. Hannon. 1995. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377:552–557.
   PubMed Web of Science ®Google Scholar
• Bunz, F., A. A. Dutriaux, C. Lengauer, T. Waldman, S. Zhou, J. P. Brown, J. M. Sedivy. K. W. Kinzler, and B. Vogelstein. 1998. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282:1497–1501.
   PubMed Web of Science ®Google Scholar
• Burns, T. F., P. Fei, K. A. Scata, D. T. Dicker, and W. S. El-Deiry. 2003. Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (Taxol)-exposed cells. Mol. Cell. Biol. 16:5556–5571.
   Google Scholar
• Cayrol, C., and B. Ducommun. 1998. Interaction of cyclin-dependent kinases and PCNA modulates proteasome-dependent degradation of p21. Oncogene 17:2437–2444.
   PubMed Web of Science ®Google Scholar
• Chan, T. A., H. Hermeking, C. Lengauer, K. W. Kinzler, and B. Vogelstein. 1999. 14-3-3 sigma is required to prevent mitotic catastrophe after DNA damage. Nature 401:616–620.
   PubMed Web of Science ®Google Scholar
• Chan, T. A., P. M. Hwang, H. Hermeking, K. W. Kinzler, and B. Vogelstein. 2000. Cooperative effects of genes controlling the G2/M checkpoint. Genes Dev. 14:1584–1588.
   PubMed Web of Science ®Google Scholar
• Chen, J., P. K. Jackson, M. W. Kirschner, and A. Dutta. 1995. Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature 374:386–388.
   PubMed Web of Science ®Google Scholar
• Chen, J., R. Peters, R. Saha, P. Lee, A. Theodoras, M. Pagano, G. Wagner, and A. Dutta. 1996. A 39 amino acid fragment of the cell cycle regulator p21 is sufficient to bind PCNA and partially inhibit DNA replication in vivo. Nucleic Acids Res. 24:1727–1733.
   PubMedGoogle Scholar
• Cheng, M., P. Olivier, J. A. Diehl, M. Fero, M. F. Roussel, J. M. Roberts, and C. J. Sherr. 1999. The p21 Cip1 and p27 Kip1 CDK ‘inhibitors’ are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J. 18:1571–1583.
   PubMed Web of Science ®Google Scholar
• Deng, C., P. Zhang, J. W. Harper, S. J. Elledge, and P. Leder. 1995. Mice lacking p21Cip1/Waf1 undergo normal development but are defective in G1 checkpoint control. Cell 82:675–684.
   PubMed Web of Science ®Google Scholar
• Dulic, V., G. H. Stein, D. F. Far, and S. I. Reed. 1998. Nuclear accumulation of p21 Cip1 at the onset of mitosis: a role at the G2/M-phase transition. Mol. Cell. Biol. 18:546–557.
   PubMed Web of Science ®Google Scholar
• El-Deiry, W. S. 1998. p21/p53, cellular growth control and genomic integrity. Curr. Top. Microbiol. Immunol. 227:121–137.
   PubMedGoogle Scholar
• El-Deiry, W. S. 2001. Akt takes centre stage in cell-cycle deregulation. Nat. Cell Biol. 3:E71–E73.
   PubMed Web of Science ®Google Scholar
• El-Deiry, W. S., T. Tokino, V. E. Velcutescu, D. B. Levy, R. Parsous, J. M. Trent, D. Lin, W. E. Mercer, K. W. Kinzler, and B. Vogelstein. 1993. Waf1, a potential mediator of p53 tumor suppression. Cell 75:817–825.
   PubMed Web of Science ®Google Scholar
• Erhardt, J. A., and R. N. Pittman. 1997. p21 Waf1 induces permanent growth arrest and enhances differentiation, but does not alter apoptosis in PC12 cells. Oncogene 16:443–451.
   Google Scholar
• Fiol, C. J., A. M. Mahrenholz, Y. Wang, R. W. Roeske, and P. J. Roach. 1987. Formation of protein kinase recognition sites by covalent modification of the substrate. Molecular mechanism for the synergistic action of casein kinase II and glycogen synthase kinase 3. J. Biol. Chem. 262:14042–14048.
   PubMed Web of Science ®Google Scholar
• Fisk, H. A., and M. Winey. 2001. The mouse Mps1p-like kinase regulates centrosome duplication. Cell 106:95–104.
   PubMed Web of Science ®Google Scholar
• Flores-Rozas, H., Z. Kelman, F. B. Dean, Z. Q. Pan, J. W. Harper, S. J. Elledge, M. O'Donnell, and J. Hurwitz. 1994. Cdk-interacting protein 1 directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase delta holoenzyme. Proc. Natl. Acad. Sci. USA 91:8655–8659.
   PubMed Web of Science ®Google Scholar
• Fotedar, R., P. Fitzgerald, T. Rousselle, D. Cannella, M. Doree, H. Messier, and A. Fotedar. 1996. p21 contains independent binding sites for cyclin and cdk2: both sites are required to inhibit cdk2 kinase activity. Oncogene 12:2155–2164.
   PubMedGoogle Scholar
• Furstenthal, L., B. K. Kaiser, C. Swanson, and P. K. Jackson. 2001. Cyclin E uses Cdc6 as a chromatin-associated receptor required for DNA replication. J. Cell Biol. 152:1267–1278.
   PubMedGoogle Scholar
• Glotzer, M., A. W. Murray, and M. W. Kirschner. 1991. Cyclin is degraded by the ubiquitin pathway. Nature 349:32–138.
   Google Scholar
• Guadagno, T. M., and J. W. Newport. 1996. Cdk2 kinase is required for entry into mitosis as a positive regulator of Cdc2-cyclin B kinase activity. Cell 84:73–82.
   PubMedGoogle Scholar
• Gulbis, J. M., Z. Kelman, J. Hurwitz, M. O'Donnell, and J. Kuriyan. 1996. Structure of the C-terminal region of p21 Waf1/Cip1 complexed with human PCNA. Cell 87:297–306.
   PubMed Web of Science ®Google Scholar
• Hall, C., D. M. Nelson, X. F. Ye, K. Baker, J. A. DeCaprio, S. Seeholzer, M. Lipinski, and P. D. Adams. 2001. HIRA, the human homologue of yeast Hir1p and Hir2p, is a novel cyclin-cdk2 substrate whose expression blocks S-phase progression. Mol. Cell. Biol. 21:1854–1865.
   PubMedGoogle Scholar
• Hall-Jackson, C. A., D. A. E. Cross, N. Morrice, and C. Smythe. 1999. ATR is a caffeine-sensitive, DNA-activated protein kinase with a substrate specificity distinct from DNA-PK. Oncogene 18:6707–6713.
   PubMed Web of Science ®Google Scholar
• Harper, J. W., G. R. Adami, N. Wei, K. Keyomarsi, and S. J. Elledge. 1993. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805–816.
   PubMed Web of Science ®Google Scholar
• Harper, J. W., S. J. Elledge, K. Keyomarsi, B. Dyndacht, L. H. Tsai, P. Zhang, S. Dobrowolski, C. Bai, L. Connell-Crowley, E. Swindell, M. P. Fox, and N. Wei. 1995. Inhibition of cyclin-dependent kinases by p21. Mol. Biol. Cell. 6:387–400.
   PubMed Web of Science ®Google Scholar
• Hartley, R. S., R. E. Rempel, and J. L. Maller. 1996. In vivo regulation of the early embryonic cell cycle in Xenopus. Dev. Biol. 173:408–419.
   PubMedGoogle Scholar
• Hengst, L., U. Gopfert, H. A. Lashuel, and S. I. Reed. 1998. Complete inhibition of Cdk/cyclin by one molecule of p21 cip1. Genes Dev. 12:3882–3888.
   PubMedGoogle Scholar
• Hoffmann, I., G. Draetta, and E. Karsenti. 1994. Activation of the phosphatase activity of human cdc25A by a CDK2 cyclin-E dependent phosphorylation at the G(1)/S transition. EMBO J. 13:4302–4310.
   PubMed Web of Science ®Google Scholar
• Hu, B., J. Mitra, S. van den Heuvel, and G. H. Enders. 2001. S and G2 phase roles for Cdk2 revealed by inducible expression of a dominant-negative mutant in human cells. Mol. Cell. Biol. 21:2755–2766.
   PubMed Web of Science ®Google Scholar
• Izumi, T., and J. L. Maller. 1995. Phosphorylation and activation of the Xenopus cdc25 phosphatase in the absence of cdc2 and CDK2 kinase-activity. Mol. Biol. Cell 6:215–226.
   PubMed Web of Science ®Google Scholar
• Jaumot, M., J. M. Estanol, O. Casanovas, X. Grana, N. Agell, and O. Bachs. 1997. The cell cycle inhibitor p21(CIP) is phosphorylated by cyclin A-CDK2 complexes. Biochem. Biophys. Res. Commun. 241:434–438.
   PubMedGoogle Scholar
• Jin, Z., D. T. Dicker, and W. S. El-Deiry. 2002. Enhanced sensitivity of G1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of simvastatin and TRAIL. Cell cycle 1:82–89.
   PubMed Web of Science ®Google Scholar
• Kaneko, Y., N. Watanabe, H. Morisaki, H. Akita, A. Fujimoto, K. Tominaga, M. Terasawa, A. Tachibana, K. Ikeda, and M. Nakanishi. 1999. Cell cycle-dependent and ATM-independent expression of human Chk1 kinase. Oncogene 18:3673–3681.
   PubMed Web of Science ®Google Scholar
• King, R. W., R. J. Deshaies, J. M. Peters, and M. W. Kirschner. 1996. How proteolysis drives the cell cycle. Science 274:1652–1659.
   PubMed Web of Science ®Google Scholar
• Kriwacki, R. W., L. Hengst, L. Tennant, S. I. Reed, and P. E. Wright. 1996. Structural studies of p21Waf1/Cip1/Sdi1 in the free and Cdk2-bound state: conformational disorder mediates binding diversity. Proc. Natl. Acad. Sci. USA 93:11504–11509.
   PubMed Web of Science ®Google Scholar
• LaBaer, J., M. D. Garrett, L. F. Stevenson, J. M. Slingerland, C. Sandhu, H. S. Chou, A. Fattaey, and E. Harlow. 1997. New functional activities for the p21 family of CDK inhibitors. Genes Dev. 11:847–862.
   PubMed Web of Science ®Google Scholar
• Li, R., S. Waga, G. J. Hannon, D. Beach, and B. Stillman. 1994. Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 371:534–537.
   PubMed Web of Science ®Google Scholar
• Li, R., G. J. Hannon, D. Beach, and B. Stillman. 1996. Subcellular distribution of p21 and PCNA in normal and repair-deficient cells following DNA damage. Curr. Biol. 6:189–199.
   PubMedGoogle Scholar
• Li, Y., C. W. Jenkins, M. A. Nichols, and Y. Xiong. 1994. Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21. Oncogene 9:2261–2268.
   PubMed Web of Science ®Google Scholar
• Luo, Y., J. Hurwitz, and J. Massague. 1995. Cell-cycle inhibition by independent CDK and PCNA binding domains in p21 cip1. Nature 375:159–161.
   PubMed Web of Science ®Google Scholar
• Macleod, K. F., N. Sherry, G. Hannon, D. Beach, T. Tokino, K. Kinzler, B. Vogelstein, and T. Jacks. 1995. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev. 9:935–944.
   PubMed Web of Science ®Google Scholar
• Morgan, D. O. 1995. Principles of CDK regulation. Nature 374:131–134.
   PubMed Web of Science ®Google Scholar
• Morgan, D. O. 1997. Cyclin dependent kinases; engines, clocks, and microprocessors. Annu. Rev. Cell Dev. Biol. 13:261–291.
   PubMed Web of Science ®Google Scholar
• Morgan, D. O. 1999. Regulation of the APC and the exit from mitosis. Nat. Cell Biol. 2:E47–E53.
   Google Scholar
• Nigg, E. A. 2001. Mitotic kinases as regulators of cell division and its checkpoints. Nat. Rev. Mol. Cell Biol. 2:21–32.
   PubMed Web of Science ®Google Scholar
• O'Conner, P. M., D. K. Ferris, M. Pagano, G. Draetta, J. Pines, T. Hunter, D. L. Longo, and K. W. Kohn. 1993. G2 delay induced by nitrogen mustard in human cells affects cyclin A/xsk2 and cyclin B1/cdc2-kinase complexes differently. J. Biol. Chem. 268:8298–8308.
   PubMedGoogle Scholar
• Pandita, T. K., H. B. Lieberman, D.-S. Lim, S. Dhar, W. Zheng, Y. Taya, and M. B. Kastan. 2000. Ionizing radiation activates the ATM kinase throughout the cell cycle. Oncogene 19:1386–1391.
   PubMed Web of Science ®Google Scholar
• Parker, S. B., G. Eichele, P. Zhang, A. Rawls, A. T. Sands, A. Bradley, E. N. Olson, J. W. Harper, and S. J. Elledge. 1995. p53-independent expression of p21 Cip1 in mouse and other terminally differentiated cells. Science 267:1024–1027.
   PubMed Web of Science ®Google Scholar
• Pines, J. 1999. Four-dimensional control of the cell cycle. Nat. Cell Biol. 1:E73—E79.
   Web of Science ®Google Scholar
• Roberts, J. M. 1999. Evolving ideas about cyclins. Cell 98:129–132.
   PubMed Web of Science ®Google Scholar
• Rosenblatt, J., Y. Gu, and D. O. Morgan,. 1992. Human cyclin-dependent kinase 2 is activated during the S and G2 phases of the cell cycle and associates with cyclin A. Proc. Natl. Acad. Sci. USA 89:2824–2828.
   PubMed Web of Science ®Google Scholar
• Rossig, L., C. Badorff, Y. Holzmann, A. M. Zeiher, and S. Dimmeler. 2002. Glycogen synthase kinase-3 couples Akt-dependent signaling to the regulation of p21Cip1 degradation. J. Biol. Chem. 277:9684–9689.
   PubMed Web of Science ®Google Scholar
• Sarcevic, B., A. Mawson, R. T. Baker, and R. L. Sutherland. 2002. Regulation of the ubiquitin-conjugating enzyme hHR6A by CDK-mediated phosphorylation. EMBO J. 21:2009–2018.
   PubMed Web of Science ®Google Scholar
• Sarkaria, J. N., S. T. Randal, E. C. Busby, A. P. Kennedy, D. E. Hill, and R. T. Abraham. 1998. Inhibition of phosphoinositides 3-kinase related kinases by the radiosensitizing agent wortmannin. Cancer Res. 58:4375–4382.
   PubMed Web of Science ®Google Scholar
• Schulman, B. A., D. L. Lindstrom, and E. Harlow. 1998. Substrate recruitment to cyclin-dependent kinase 2 by a multipurpose docking site on cyclin A. Proc. Natl. Acad. Sci. USA 95:10453–10458.
   PubMed Web of Science ®Google Scholar
• Scott, M. T., N. Morrice, and K. L. Ball. 2000. Reversible phosphorylation at the C-terminal regulatory domain of p21 waf1/Cip1 modulates proliferating cell nuclear antigen binding. J. Biol. Chem. 275:11529–11537.
   PubMedGoogle Scholar
• Sherr, C. J. 1993. Mammalians G1 cyclins. Cell 73:1059–1065.
   PubMed Web of Science ®Google Scholar
• Sherr, C. J. 1994. G1 phase progression: cycling on cue. Cell 79:551–555.
   PubMed Web of Science ®Google Scholar
• Sherr, C. J., and J. M. Roberts. 1999. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13:1501–1512.
   PubMed Web of Science ®Google Scholar
• Spruck, C. H., K.-A. Won, and S. I. Reed. 1999. Deregulated cyclin E induces chromosome instability. Nature 401:297–300.
   PubMed Web of Science ®Google Scholar
• Stewart, Z. A., S. D. Leach, and J. A. Pietenpol. 1999. p21 (Waf1/Cip1) inhibition of cyclin E/Cdk2 activity prevents endoreduplication after mitotic spindle disruption. Mol. Cell. Biol. 19:205–215.
   PubMed Web of Science ®Google Scholar
• Toyoshima-Morimoto, F., E. Taniguchi, N. Shinya, A. Iwamatsu, and E. Nishida. 2001. Polo-like kinase 1 phosphorylates cyclin B1 and targets it to the nucleus during prophase. Nature 410:215–220.
   PubMed Web of Science ®Google Scholar
• Waga, S., G. J. Hannon, D. Beach, and B. Stillman. 1994. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369:574–578.
   PubMed Web of Science ®Google Scholar
• Waga, S., and B. Stillman. 1998. Cyclin-dependent kinase inhibitor p21 modulates the DNA primer-template recognition complex. Mol. Cell. Biol. 18:4177–4187.
   PubMedGoogle Scholar
• Waldmann, T., C. Lengauer, K. Kinzler, and B. Vogelstein. 1996. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 381:713–716.
   PubMedGoogle Scholar
• Warbrick, E. 1998. PCNA binding through a conserved motif. BioEssays 20:195–199.
   PubMedGoogle Scholar
• Warbrick, E., D. P. Lane, D. M. Glover, and L. S. Cox. 1995. A small peptide inhibitor of DNA replication defines the site of interaction between the cyclin-dependent kinase inhibitor p21 waf1 and proliferating cell nuclear antigen. Curr. Biol. 5:275–282.
   PubMed Web of Science ®Google Scholar
• Wei, Y., H. P. Jin, and J. W. Harper. 2003. The cyclin E/Cdk2 substrate and Cajal body component p220 (NPAT) activates histone transcription through a novel LisH-Like domain. Mol. Cell. Biol. 23:3669–3680.
   PubMed Web of Science ®Google Scholar
• Xiong, Y., G. J. Hannon, H. Zhang, D. Casso, R. Kobayashi, and D. Beach. 1993. p21 is a universal inhibitor of cyclin kinases. Nature 366:701–704.
   PubMed Web of Science ®Google Scholar
• Xiong, Y., H. Zhang, and D. Beach. 1992. D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA. Cell 71:505–514.
   PubMed Web of Science ®Google Scholar
• Ye, X., Y. Wei, G. Nalepa, and J. W. Harper. 2003. The cyclin E/Cdk2 substrate p220 (NPAT) is required for S-phase entry, histone gene expression, and Cajal body maintenance in human somatic cells. Mol. Cell. Biol. 23:8586–8600.
   PubMed Web of Science ®Google Scholar
• Zhang, H., Y. Xiong, and D. Beach. 1993. Proliferating cell nuclear antigen and p21 are components of multiple cell cycle kinase complexes. Mol. Biol. Cell. 4:897–906.
   PubMed Web of Science ®Google Scholar
• Zhang, H., G. J. Hannon, and D. Beach. 1994. p21-containing cyclin kinases exists in both active and inactive states. Genes Dev. 8:1750–1758.
   PubMed Web of Science ®Google Scholar
• Zhang, H., G. J. Hannon, D. Casso, and D. Beach. 1994. p21 is a component of active cell cycle kinases. Cold Spring Harbor Symp. Quant. Biol. 59:21–29.
   PubMedGoogle Scholar
• Zhou, B.-B. S., P. Chaturvedi, K. Spring, K., S. P. Scott, R. A. Johnson, R. Mishra, M. R. Mattern, J. D. Winkler, and K. K. Khanna. 2000. Caffeine abolishes the mammalian G2/M DNA damage checkpoint by inhibiting ataxia-telangiectasia-mutated kinase activity. J. Biol. Chem. 275:10342–10348.
   PubMed Web of Science ®Google Scholar
• Zhou, B. P., Y. Liao, W. Xia, B. Spohn, M.-H. Lee, and M. C. Hung. 2001. Cytoplasmic localization of p21 Cip1/Waf1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat. Cell Biol. 3:245–251.
   PubMed Web of Science ®Google Scholar